Bellicum Pharmacueticals Inc. (NASDAQ:BLCM)’s share price was up 2.5% during trading on Thursday . The company traded as high as $14.40 and last traded at $14.18, with a volume of 125,942 shares traded. The stock had previously closed at $13.84.

A number of equities analysts have commented on BLCM shares. SunTrust Banks Inc. started coverage on shares of Bellicum Pharmacueticals in a research note on Thursday, June 2nd. They issued a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research upgraded shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research note on Monday, July 11th. Finally, Piper Jaffray Cos. restated a “buy” rating on shares of Bellicum Pharmacueticals in a research note on Saturday, July 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $28.00.

The stock’s 50-day moving average price is $13.21 and its 200-day moving average price is $11.27. The firm’s market cap is $374.00 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. Analysts predict that Bellicum Pharmacueticals Inc. will post ($2.22) EPS for the current year.

In related news, VP Ken Moseley sold 15,000 shares of the business’s stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total transaction of $195,000.00. Following the transaction, the vice president now directly owns 15,196 shares in the company, valued at $197,548. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Kevin M. Slawin sold 2,719 shares of the business’s stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $13.99, for a total transaction of $38,038.81. Following the transaction, the chief technology officer now owns 134,206 shares in the company, valued at $1,877,541.94. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley raised its position in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent SEC filing.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.